3/6
10:07 am
bbot
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
Low
Report
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
3/6
08:03 am
bbot
BridgeBio Oncology Therapeutics (BBOT) had its price target raised by HC Wainwright from $27.00 to $29.00. They now have a "buy" rating on the stock.
Low
Report
BridgeBio Oncology Therapeutics (BBOT) had its price target raised by HC Wainwright from $27.00 to $29.00. They now have a "buy" rating on the stock.
3/5
04:05 pm
bbot
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
Medium
Report
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
2/12
04:05 pm
bbot
BBOT to Participate in Upcoming Investor Healthcare Conferences
Low
Report
BBOT to Participate in Upcoming Investor Healthcare Conferences
2/11
04:05 pm
bbot
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2/10
06:05 pm
bbot
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) was given a new $23.00 price target on by analysts at Stifel Nicolaus.
Medium
Report
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) was given a new $23.00 price target on by analysts at Stifel Nicolaus.
1/27
02:07 pm
bbot
Biotech investor Cormorant secures $150M for another SPAC deal [Yahoo! Finance]
Low
Report
Biotech investor Cormorant secures $150M for another SPAC deal [Yahoo! Finance]
1/23
08:44 am
bbot
Helix Acquisition prices $150M initial public offering [Seeking Alpha]
High
Report
Helix Acquisition prices $150M initial public offering [Seeking Alpha]
1/15
04:40 pm
bbot
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is now covered by analysts at
Weiss Ratings. They set a "sell (d+)" rating on the stock.
Low
Report
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is now covered by analysts at
Weiss Ratings. They set a "sell (d+)" rating on the stock.
1/15
04:01 pm
bbot
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) was upgraded by analysts at Raymond James Financial, Inc. to a "moderate buy" rating.
Low
Report
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) was upgraded by analysts at Raymond James Financial, Inc. to a "moderate buy" rating.
1/13
04:05 pm
bbot
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1/7
07:00 am
bbot
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Ka Pipeline Programs
Medium
Report
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Ka Pipeline Programs
12/16
04:05 pm
bbot
BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference